See more : Urstadt Biddle Properties Inc. (UBP-PH) Income Statement Analysis – Financial Results
Complete financial analysis of Personalis, Inc. (PSNL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Personalis, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- NIFTY Lifestyle Co., Ltd. (4262.T) Income Statement Analysis – Financial Results
- DEFAMA Deutsche Fachmarkt AG (DEF.DE) Income Statement Analysis – Financial Results
- Yuyu Pharma, Inc. (000225.KS) Income Statement Analysis – Financial Results
- Empower Clinics Inc. (EPW.CN) Income Statement Analysis – Financial Results
- Blue Moon Metals Inc. (MOON.V) Income Statement Analysis – Financial Results
Personalis, Inc. (PSNL)
About Personalis, Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 73.48M | 65.05M | 85.49M | 78.65M | 65.21M | 37.77M | 9.39M |
| Cost of Revenue | 55.27M | 51.70M | 53.84M | 58.53M | 43.13M | 25.97M | 11.74M |
| Gross Profit | 18.21M | 13.35M | 31.66M | 20.11M | 22.08M | 11.81M | -2.34M |
| Gross Profit Ratio | 24.78% | 20.52% | 37.03% | 25.57% | 33.86% | 31.25% | -24.94% |
| Research & Development | 64.78M | 64.91M | 49.31M | 28.57M | 22.42M | 14.30M | 9.92M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.27M | 9.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.73M | 63.97M | 47.70M | 33.69M | 22.08M | 11.27M | 9.90M |
| Other Expenses | 13.64M | 61.00K | -42.00K | -24.00K | -1.44M | -33.00K | -227.00K |
| Operating Expenses | 128.14M | 128.88M | 97.01M | 62.26M | 44.50M | 25.58M | 19.82M |
| Cost & Expenses | 183.42M | 180.58M | 150.85M | 120.79M | 87.63M | 51.54M | 31.56M |
| Interest Income | 5.90M | 2.40M | 367.00K | 949.00K | 1.62M | 293.00K | 100.00K |
| Interest Expense | 110.00K | 201.00K | 184.00K | 2.00K | 1.13M | 1.89M | 1.30M |
| Depreciation & Amortization | 11.30M | 12.88M | 8.96M | 7.17M | 5.73M | 3.07M | 1.22M |
| EBITDA | -96.81M | -104.64M | -59.01M | -34.05M | -18.21M | -14.92M | -21.07M |
| EBITDA Ratio | -131.74% | -173.83% | -76.06% | -45.09% | -34.10% | -27.65% | -224.36% |
| Operating Income | -109.94M | -115.53M | -65.35M | -42.15M | -22.42M | -13.77M | -22.16M |
| Operating Income Ratio | -149.61% | -177.61% | -76.44% | -53.59% | -34.38% | -36.45% | -235.95% |
| Total Other Income/Expenses | 1.72M | 2.26M | 141.00K | 923.00K | -2.66M | -6.11M | -1.43M |
| Income Before Tax | -108.21M | -113.28M | -65.21M | -41.22M | -25.08M | -19.88M | -23.59M |
| Income Before Tax Ratio | -147.27% | -174.14% | -76.28% | -52.41% | -38.45% | -52.63% | -251.18% |
| Income Tax Expense | 83.00K | 40.00K | 14.00K | 57.00K | 9.00K | 7.00K | 5.00K |
| Net Income | -108.30M | -113.32M | -65.23M | -41.28M | -25.08M | -19.89M | -23.60M |
| Net Income Ratio | -147.38% | -174.20% | -76.29% | -52.49% | -38.47% | -52.64% | -251.23% |
| EPS | -2.25 | -2.48 | -1.49 | -1.06 | -0.80 | -0.91 | -1.08 |
| EPS Diluted | -2.25 | -2.48 | -1.49 | -1.06 | -0.80 | -0.91 | -1.08 |
| Weighted Avg Shares Out | 48.18M | 45.70M | 43.89M | 39.11M | 31.24M | 21.75M | 21.75M |
| Weighted Avg Shares Out (Dil) | 48.18M | 45.70M | 43.89M | 39.11M | 31.24M | 21.75M | 21.75M |
Personalis, Inc. (PSNL) Q4 2022 Earnings Call Transcript
A Short Guide to Making Money With Penny Stocks in 2023
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
Personalis: Looking For A Potential Turnaround In 2023
Personalis, Inc. (PSNL) Q3 2022 Earnings Call Transcript
Personalis (PSNL) Reports Q3 Loss, Misses Revenue Estimates
Personalis to Announce Third Quarter 2022 Financial Results
Personalis to Announce Third Quarter 2022 Financial Results
5 Top Stocks Cathie Wood Bought This Week
Personalis, Inc. (PSNL) CEO John West on Q2 2022 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports